Investigating a new RNA's role in aggressive thyroid cancer
Official title: Role of newly identified, thyroid-specific LincRNA in BRAFV600E thyroid carcinoma
Funded at Beth Israel Deaconess Medical Center · NIH-10769868 · Data updated 2026-11-12
This study is looking at a tough type of thyroid cancer called BRAFV600E-papillary thyroid carcinoma to see how a newly discovered RNA affects how the cancer uses iodine and survives, with the goal of finding better treatment options for patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beth Israel Deaconess Medical Center NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | March 1, 2020 |
| Project end | February 28, 2026 |
| Funding year | 2024 |
| Award (this year) | $380,298 |
| NIH project number | 5R01CA248031-05 |
| Project ID | NIH-10769868 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with BRAFV600E-papillary thyroid carcinoma who have shown resistance to current therapies.
✕Less likely to help
Patients with other types of thyroid cancer or those who do not have the BRAFV600E mutation may not benefit from this research.
What this research studies
This research focuses on BRAFV600E-papillary thyroid carcinoma, a particularly aggressive form of thyroid cancer that is resistant to traditional treatments. The study aims to understand how a newly identified thyroid-specific long intergenic non-coding RNA (lincRNA) affects iodine metabolism and tumor cell survival. By exploring the cellular mechanisms involved, the researchers hope to identify new treatment strategies that could improve patient outcomes. The project utilizes advanced techniques such as CRISPR to manipulate gene expression and assess the impact on cancer cell behavior.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with BRAFV600E thyroid carcinoma, potentially improving survival rates and reducing recurrence.
How similar studies have gone: Other research has shown promise in targeting similar epigenetic mechanisms in cancer treatment, suggesting that this approach could be viable.
Where this research is happening
-
Beth Israel Deaconess Medical Center
Boston, United States Active
Researchers
- Principal investigator: Nucera, Carmelo — Beth Israel Deaconess Medical Center
- Study coordinator: Nucera, Carmelo
Related research
Other NIH-funded projects on the same topics.
-
How support cells (fibroblasts) affect thyroid cancer growth
This research looks at whether certain support cells called cancer-associated fibroblasts, marked by FAP and Wnt signals, help some thyroid cancers become more aggressive so tests or treatments can be developed.
-
Investigating how cancer-associated fibroblasts affect thyroid cancer.
This study is looking at how certain cells in the thyroid can affect the growth of thyroid cancer, with the hope of finding new ways to improve treatment for patients like you.
-
Investigating how certain cells in thyroid cancer affect disease progression
This study is looking at how certain cells in the thyroid, called cancer-associated fibroblasts, help aggressive thyroid cancers grow and spread, with the hope of finding new ways to predict and improve treatment for patients with these tough-to-treat cancers.
-
Investigating how Wnt signaling affects aggressive thyroid cancer
This study is looking at how certain signals in the body affect aggressive thyroid cancers that come back after treatment, and it aims to find new ways to help patients by testing how these cancers respond to specific drugs.
-
Novel idea: Epstein-Barr virus and eye cancer in people living with HIV in Zimbabwe
A study explores whether Epstein-Barr virus could cause a type of eye cancer in people living with HIV in Zimbabwe.
-
Glutamine and macrophage behavior in liver cancer
A funded project at a medical university aims to understand how the liver’s immune cells interact with a specific type of liver cancer by looking at metabolism, especially glutamine and ammonia.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.